N-of-One, QIAGEN Take Precision Drug Development to the Next Level:QIAGEN's Molecular Oncology Decision Support solutions—now enhanced by the N-of-One acquisition—powers drug discovery and clinical development

摘要

In late 2018, QIAGEN, a leading molecular diagnostics and precision medicine company, acquired molecular oncology decision support company N-of-One.This move enabled QIAGEN to enhance its sample-to-insight solution offering with its clinical laboratory customers in molecular oncology testing from assay design to test interpretation—and to develop a new real-world data (RWD)-based solution offering for pharma and payers spanning basic research and discovery, through clinical development, to the development of companion diagnostic (CDx) products for approved therapies.